Open Access
Review Article

September-October 2026, Vol. 02 (5), 76-82

International Journal of Pharmaceutical

Research and Medicinal Plants

(An International Peer Reviewed Journal)

Integrated Network Pharmacology, ADMET Profiling, and Molecular
Docking Investigation of Losartan and Its Active Metabolite against
Angiotensin-Related Target

Nepolean R¹, Chandramohan K² and
Ramesh K
³*

1
Principal, Thanthai Roever College of Pharmacy, Peramabalur, Tamilnadu, India

2
Professor & Head, Dept. of Pharmaceutics, Thanthai Roever College of Pharmacy, Peramabalur, Tamilnadu, India

3*
Assistant Professor, Thanthai Roever College of Pharmacy, Department of Pharmacy Practice, Tamilnadu, India

ARTICLE INFO:
ABSTRACT

Received:
04
th
Oct.
2026
;
Received
in
revised form: 18
th
Oct. 2026
;
Accepted:
27
th
Oct.
2026
;
Available
online:
30
th
Oct. 2026.

Keywords:
Losartan; Active Metabolite;
Network Pharmacology; ADMET;
Molecular Docking; Angiotensin
Signaling.

DOI:
https://doi.org/10.61280/4sa10p81

*Corresponding Author:
Ramesh K

Email:
rameshprofdr@gmail.com

Losartan is a widely prescribed angiotensin II receptor blocker whose
therapeutic
activity
is
influenced
by
its
active
metabolites.
Despite
extensive clinical use, the broader molecular interaction landscape of
losartan
and
its
metabolites
remains
insufficiently
characterized.
In
this
study,
an
integrated
computational
strategy
combining
network
pharmacology,
in
silico
ADMET
profiling,
and
molecular
docking
was employed to
investigate the multi-target
interaction potential of
losartan
and
its
active
metabolite.
Network
pharmacology
analysis
revealed
a
signaling-centric
target
network
enriched
in
angiotensin-
related pathways, kinases, and apoptosis-associated proteins. ADMET
profiling
demonstrated
favorable
oral
drug-likeness
alongside
identifiable
metabolic
liabilities,
particularly
cytochrome
P450
inhibition.
Molecular
docking
against
the
angiotensin-associated
protein structure (PDB ID: 4YAY) revealed stable and energetically
favorable
binding,
with
blind
docking
yielding
a
best
affinity
of
−8.897 kcal/mol. These findings provide mechanistic insight into the
polypharmacological behavior of losartan and its metabolite.

1. INTRODUCTION

Hypertension remains a major global health burden and a critical risk factor for cardiovascular, renal, and
cerebrovascular diseases. When there is a blockage which prevents the blood flow to heart or brain often
causes heart attacks and strokes The cause of heart attack and stroke is usually a combination of risk factors
like tobacco usage, unhealthy diet, obesity, physical inactivity, diabetes, hypertension and hyperlipidema[1].
Heart attack and stroke create enormous economic and health burdens in India and also internationally[2] [3].
In Asia, which is about 60 percent of world’s population and many of its countries are developing economic
countries, strokes are very serious issue. In cardio vascular disease, high blood pressure and hypertension are
the most important
risk factors leading
to
mortality.
Angiotensin II receptor blockers (ARBs) represent
a
cornerstone
of
antihypertensive
therapy.
Losartan,
the
first
clinically
approved
ARB,
continues
to
be

Copyright:
©
Author
2026
by
the
Author.
International
Journal
of
Pharmaceutical
Research
and
Medicinal
Plants
Published
by
Informative Journals
(Jadoun Science Publishing Group India). This article is an open access article distributed under the terms and conditions
of the CC BY-NC-ND 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 76

extensively prescribed worldwide. Beyond its parent compound, losartan undergoes hepatic metabolism to
form pharmacologically active metabolites that significantly contribute to therapeutic efficacy[4-7]. Previous
investigations
have
largely
focused
on
losartan
as
a
selective
angiotensin
II
type-1
receptor
antagonist.
Recent computational studies highlight the importance of polypharmacology in explaining pleiotropic drug
effects.
However,
integrated
studies
combining
network
pharmacology,
ADMET
profiling,
and
docking
validation
remain
limited[8].
Emerging
evidence
suggests
that
losartan
and
its
metabolites
may
exert
biological
effects
beyond
angiotensin
II
receptor
antagonism,
including
modulation
of
inflammatory,
apoptotic, and metabolic signaling pathways. Network pharmacology is a multidisciplinary field of research
that combines computational and experimental methods to integrate large amounts of information to make
new discoveries. Network pharmacology is a new discipline based on the theory of systems biology, network
analysis of biological systems, and selection of specific signal nodes for multi-target drug molecular design
[11]. Network pharmacology, integrated with molecular docking and pharmacokinetic evaluation, offers a
system-level
framework
to
elucidate
such
multi-target
interactions.
The
present
study
investigates
the
molecular interaction profile of losartan and its active metabolite using this integrative approach. [9,10]

2. MATERIALS AND METHODS

Putative protein targets were identified using SwissTargetPrediction and ChEMBL databases. Targets were
standardized to official gene symbols prior to network construction. ADMET profiling was performed using
machine-learning-driven
in
silico
tools.
Molecular
docking
was
carried
out
using
AutoDock
Vina
against
PDB ID: 4YAY, employing blind docking to ensure unbiased binding site exploration. [6,7,8].

2.1. Selection of receptor protein.

RCSB is the single, global archive for information about the 3D structure of macromolecules (proteins and
DNA)
and
their
complexes,
as
determined
by
X-ray
crystallography,
NMR
spectroscopy
(http://www.rcsb.org/pdb/home/home.do). The PDB file was cleaned and the heteroatoms (HETATM) of the
receptor were removed manually, since these are non-standard residues of protein.

2.2. Ligand preparation

Generation of ligand from PubChem compound database (
http://www.ncbi.nlm.nih.gov/pccompound
) and it is
redrawn
using
ACD
chemsketch
12.01.
A
range
of
conformers
for
each
ligand
were
created
(energy
minimization)
by
using
Steepest
descent
method
in
UCSF
Chimera
and
the
lowest
energy
conformer
was
chosen for further evaluation.

2.3. Docking

Docking studies were performed using Autodock Vina 1.1.2. Ligand can be uploaded at the same time with
the given protein target and software generates integrated docking, post analysis and graphical visualization
showing
the
favorable
docked
poses
within
the
protein
target.
Data
related
to
free
energy
(E),
hydrogen
bonding (H), Van der Waal (VdW) and electrostatic functions can be obtained.

2.4 ADMET analysis

A drug molecule needs to reach its target in the body at a concentration high enough and remain there in a
bioactive form for the anticipated biological events to take place in order for it to be effective as a medication
[12]. In the process of developing new drugs, absorption, distribution, metabolism, and excretion (ADME)
are evaluated in progressively earlier stages of the discovery phase, when the number of potential compounds
is
high
but
physical
sample
access
is
restricted.
A
variety
of
quick
and
reliable
predictive
models
for
physicochemical
properties,
pharmacokinetics,
drug-likeness,
and
medicinal
chemistry
friendliness
are
available via the new SwissADME web tool. These models include highly skilled internal techniques, such as
the BOILED Egg and Bioavailability Radar. The user-friendly interface provided by the log-in-free website
http://www.swissadme.ch allowed for easy and efficient input and interpretation in this study

Ramesh K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 76-82
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 77

4. Results and Discussion

4.1 Network Pharmacology Analysis [4,5]

Network
analysis
revealed
enrichment
of
angiotensin-related
proteins,
kinases,
and
apoptosis-associated
regulators.
Graph-theoretical
interpretation
indicated
a
non-random
topology
characterized
by
highly
connected
hub
proteins
(Figure
1),
suggesting
a
systems-level
mode
of
action.
Network
pharmacology
analysis successfully identified key protein targets, prominently including Losartan, Type-1 angiotensin II
receptor,
Cytochrome
P450
2C9,
Angiotensin-converting
enzyme,
Prostanoid
EP4
receptor,
and
enriched
biological
pathways
associated
with
Losartan.
The
detailed
insights
from
the
enhanced_top_five_chembl_targets
DataFrame
significantly
contribute
to
understanding
the
compound's
primary
mechanisms.
The
rigorous
data
preprocessing,
including
target
name
standardization,
proved
essential for generating biologically meaningful insights. The identified protein targets and their involvement
in
critical
metabolic
and
signaling
pathways
highlight
the
multi-target
nature
of
Losartan's
action.
These
findings
provide a solid foundation for
further
experimental validation and drug development,
suggesting
promising avenues for understanding
its therapeutic potential and optimizing its application. Compound
-
target interaction derived from network pharmacology analysis is derived in
Figure 1.

Figure 1.
Compound–target interaction network derived from network pharmacology analysis.

4.2 ADMET Profiling [8]

ADMET analysis indicated favorable physicochemical properties and oral bioavailability, while extensive
predicted cytochrome P450 inhibition highlighted potential metabolic liabilities (Figure 2,3; Table 2). [8]

Ramesh K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 76-82
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 78
Bioavailability Radar (Rectangle)

Figure 2. Pathway enrichment analysis
highlighting angiotensin-related signaling
pathways.

Figure 3. ADMET and pharmacokinetic
property predictions of the investigated
compound.

The integrated ADMET profiling of the investigated compound highlights several properties consistent with
drug-like
chemical
space
shown
in
Table
1.
The
physicochemical
profile,
including
molecular
weight,
lipophilicity, and polar surface area, aligns well with established oral drug design principles, supporting its
potential for adequate absorption.

Table 1:
Summarized ADMET analysis results.

S.No.

Molecule

Mol MW

Log p

TPSA

Log s

1.

Losartan

422.92

4.27

92.51

-4.72

4.3 Molecular Docking Analysis

Docking
against
the
angiotensin-associated
protein
(PDB
ID:
4YAY)
demonstrated
stable
ligand–protein
interactions.
Blind
docking
produced
a
best
binding
affinity
of
−8.897
kcal/mol
(Table
2,3).
Key
hydrophobic and polar interactions supported binding stability. 2ad diagram of ligand losartan with Protein
4YAY is figured in
Figure 4.

Table 2:
Comparative Molecular Docking Results

Ligand

Target Protein

PDB ID

Docking Score
(kcal/mol)

Key Interaction Remarks

Losartan

Angiotensin-associated
protein

4YAY

-8.897

Strong hydrophobic and
polar interactions

Losartan

Angiotensin-associated
protein

4YAY

-5.543

Fixed-grid docking,
moderate affinity

Active metabolite
(EXP-3179)

Angiotensin-associated
protein

4YAY

-8.2

Stable binding with
conserved residues

Ramesh K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 76-82
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 79

Table 3
. Expanded Comparative Molecular Docking Results with Interaction Residues and Pose Statistics

Ligand

Target Protein

PDB ID

Best
Docking
Score
(kcal/mol)

Top 5
Poses
(Mean ±
SD)

Key
Interaction
Residues

Docking
Mode

Losartan

Angiotensin-
associated
protein

4YAY

-8.897

−8.42 ±
0.31

TYR35,
TRP84,
THR88,
TYR92,
VAL108

Blind
docking

Losartan

Angiotensin-
associated
protein

4YAY

-5.543

−5.21 ±
0.27

TYR35,
VAL108,
ILE288

Fixed-grid
docking

Active
metabolite
(EXP-3179)

Angiotensin-
associated
protein

4YAY

-8.200

−7.86 ±
0.34

TRP84,
THR88,
TYR92,
ILE288

Blind
docking

Figure 4:
2D Interaction Plot (Ligand1 - Blind Docking with 4YAY): A 2D plot detailing the ligand and its
interactions with protein residues, with relevant atoms highlighted.

More
recent
computational
and
systems
pharmacology
studies
have
expanded
this
understanding
by
revealing
interactions
of
angiotensin
receptor
blockers
with
a
broader
spectrum
of
molecular
targets,
including
kinases,
cytochrome
P450
enzymes,
metalloproteinases,
and
apoptosis-associated
proteins.
Network-based
analyses
have
shown
that
these
targets
are
embedded
within
interconnected
signaling

Ramesh K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 76-82
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 80

pathways such as MAPK signaling, inflammatory cascades, and apoptotic regulation, suggesting potential
pleiotropic biological effects.

The present research contributes to this evolving body of literature by integrating network pharmacology,
ADMET
profiling,
and
molecular
docking
into
a
unified
analytical
framework.
By
validating
network-
predicted targets through docking against an angiotensin-associated protein structure (PDB ID: 4YAY) and
contextualizing
these interactions within pharmacokinetic constraints, this study provides mechanistic and
structural continuity that strengthens the biological plausibility of multi-target modulation by losartan and its
active metabolite. Heatmap shows the percentage of each amino acid in different protein chains in
Figure 5.

Figure 5
: Amino Acid Composition Percentage Across Protein Chains: This heatmap shows the percentage
of each amino acid in different protein chains.

5. CONCLUSION AND FUTURE DIRECTIONS

This integrated computational investigation demonstrates that losartan and its active metabolite exhibit multi-
target interaction potential, supported by network pharmacology, ADMET profiling, and molecular docking
validation.
Molecular
docking
against
PDB
ID:
4YAY
supplied
structural
evidence
supporting
feasible
ligand–protein
interactions,
thereby
linking
network
topology
with
binding
energetics
and
residue-level
interaction stability. Future studies incorporating molecular dynamics simulations and experimental assays
are warranted.

REFERENCES

  1. 1.
    Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA,Connor M, Bennett DA, et al.
    Global
    burden of diseases and risk factors study 2010 (GBD 2010) and the GBD stroke experts group global
    and regional burden of stroke during 1990-2010: Findings from the global burden of disease study
    2010
    . Lancet 2014
    ;383:245-54.
  2. 2.
    He
    J,
    Whelton
    PK.
    Elevated
    systolic
    blood
    pressure
    and
    risk
    of
    cardiovascular
    and
    renal
    disease:
    Overview of evidence from observational epidemiologic studies and randomized controlled trials
    . Am
    Heart J 1999
    ;138:211-9.
  3. 3.
    Carson AP, Howard G, Burke GL. Ethnic differences in hypertension incidence among middle-aged
    and older adults: The multi-ethnic study of atherosclerosis.
    Hypertension 2011
    ;57:1101-7.
Ramesh K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 76-82
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 81
  1. 4.
    Hopkins
    AL.
    Network
    pharmacology:
    the
    next
    paradigm
    in
    drug
    discovery.
    Nat
    Chem
    Biol.
    2008;4:682–690.
  2. 5.
    Zhou W, Wang Y. Network-based drug–target interaction analysis. Mol Biosyst. 2014;10:101–110.
  3. 6.
    Morris
    GM,
    Huey
    R,
    Olson
    AJ.
    Using
    AutoDock
    for
    ligand–receptor
    docking.
    Curr
    Protoc
    Bioinformatics. 2008.
  4. 7.
    Trott
    O,
    Olson
    AJ.
    AutoDock
    Vina:
    improving
    docking
    speed
    and
    accuracy.
    J
    Comput
    Chem.
    2010;31:455–461.
  5. 8.
    Wishart DS et al. DrugBank 5.0: a major update. Nucleic Acids Res. 2018;46:D1074–D1082.
  6. 9.
    Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904–912.
  7. 10.
    Lo
    MW
    et
    al.
    Pharmacokinetics
    of
    losartan
    and
    its
    active
    metabolite.
    Clin
    Pharmacokinet.
    1995;29:347–356.
  8. 11.
    Li
    Zhoa,
    Hong
    Zhang,
    Ning
    Li,
    Hoa
    Xu,
    et
    al.
    Network
    pharmacology,
    a
    promising
    approach
    to
    reveal the pharmacology mechanism of chinese medicine formulation.
    J Ethanopharmacol.
    2023;309:
    116306 DOI:
    10.1016/j.jep.2023.116306
  9. 12.
    Daina,
    O.
    Michielin,
    V.
    Zoete,
    SwissADME:
    a
    free
    web
    tool
    to
    evaluate
    pharmacokinetics,
    drug-
    likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017) 42717 DOI:
    10.1038/srep42717

How
to
cite
this
article:
Chandramohan
K,
Nepolean
R,
Ramesh
K,
Integrated
Network
Pharmacology,
ADMET
Profiling,
and
Molecular
Docking
Investigation
of
Losartan
and
Its
Active
Metabolite
Against
Angiotensin-Related
Target.
(2026).
International
Journal of Pharmaceutical Research and Medicinal Plants
,
2
(5),63-69.
https://doi.org/10.61280/4sa10p81

Published by:

Informative Journals

Jadoun Science Publishing Group India

Ramesh K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 76-82
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 82